Published • loading... • Updated
ArkBio’s RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial - Business News Week
Summary by businessnewsweek.in
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
ArkBio’s RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial - Business News Week
SHANGHAI, Aug. 14, 2026 /PRNewswire/ — Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”) today announced that the U.S. Food and Drug Administration (FDA) has approved ziresovir (AK0529) for a phase II clinical trial in the severely ill RSV infected infant patients, including the ones in pediatric intensive care unit (PICU). Severe RSV Infection: An Urgent Unmet Need […] The post ArkBio’s RSV Antiviral Drug Ziresovir Receives FDA Approval for P…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
